Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | GNRHR | P30968 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159031 | 0.93 | NMUR2 (0.57) | APLNRNMUR2NMUR1NTSR1OPRM1 | |
| SCHEMBL30158799 | 0.92 | OPRM1 (0.59) | APLNRNMUR2NMUR1NTSR1OPRM1 | |
| SCHEMBL29836800 | 0.90 | SLC6A2 (0.56) | NMUR2NMUR1OPRM1OPRD1GNRHR | |
| SCHEMBL30785950 | 0.87 | OPRM1 (0.57) | APLNRNMUR2NMUR1NTSR1OPRM1 | |
| SCHEMBL30974363 | 0.86 | NTSR1 (0.56) | NTSR1CXCL8 | |
| SCHEMBL30527820 | 0.85 | SLC6A2 (0.58) | NMUR2NMUR1OPRM1OPRD1SLC6A2 | |
| SCHEMBL31433368 | 0.85 | REN (0.52) | APLNRNMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL1674814 | 0.85 | OPRM1 (0.55) | NTSR1OPRM1OPRD1SLC6A2 | |
| SCHEMBL1674810 | 0.85 | OPRM1 (0.55) | NTSR1OPRM1OPRD1SLC6A2 | |
| SCHEMBL22400261 | 0.85 | OPRM1 (0.55) | NTSR1OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292642-B | Third-generation epidermal growth factor receptor inhibitor drug-resistant mutation neoantigen and application thereof | 倍而达药业(苏州)有限公司 | 2023-02-28 | — | — | CN | disclosed |